本议案已经公司董事会薪酬与考核委员会审议通过。具体内容详见公司 同日在巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。 证券代码：300149 证券简称：睿智医药 公告编号：2025-52 睿智医药科技股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第九次会议 于 2025 年 7 月 11 日以通讯方式召开。会议通知以书面、电话或电子邮件方式 送达。会议应到董事 6 人，实到 6 人。会议由公司董事长WOO SWEE LIAN先 生主持，公司高级管理人员列席了会议。本次会议召集与召开符合有关法律、 行政法规、部门规章和《公司章程》的有关规定。经与会董事认真审议，形成 决议如下： 1、审议通过了《关于调整2025年限制性股票激励计划首次授予激励对象 名单和授予数量的议案》 根据《上市公司股权激励管理办法》、公司《2025年限制性股票激励计划 （草案）》及《2025年限制性股票激励计划实施考核管理办法》，由于1名激励 对象因个人原因已离职，已不具备激 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-55 睿智医药科技股份有限公司 关于向激励对象首次授予限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、限制性股票首次授予日：2025 年 7 月 11 日 2、限制性股票首次授予数量：4,456.00 万股，占公司目前股本总额 49,796.3992 万股的 8.95%。 3、股权激励方式：第二类限制性股票。 根据《睿智医药科技股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）的规定，睿智医药科技股份有限公司（以 下简称"公司"或"睿智医药"）2025 年限制性股票激励计划（以下简称"本激 励计划"）授予条件已成就，根据公司 2024 年年度股东会的授权，公司于 2025 年 7 月 11 日召开第六届董事会第九次会议，审议通过了《关于向激励对象首次 授予限制性股票的议案》，确定 2025 年 7 月 11 日为首次授予日，以 3.05 元/股 的授予价格向 123 名激励对象授予 4,456.00 万股限制性股票。现将有关 ...

睿智医药科技股份有限公司 自愿性信息披露管理制度 第一章 总则 第一条 为规范睿智医药科技股份有限公司（以下简称"公司"）自愿性信 息披露行为，确保公司自愿性信息披露的真实、准确、完整与标准统一，切实保 护公司、股东及投资者的合法权益，根据《中华人民共和国证券法》（以下简称 《证券法》）《上市公司信息披露管理办法》《深圳证券交易所创业板股票上市 规则》（以下简称《股票上市规则》）《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》（以下简称《规范运作指引》）等相关法 律法规、规范性文件以及《睿智医药科技股份有限公司章程》（以下简称《公司 章程》）《睿智医药科技股份有限公司信息披露事务管理制度》（以下简称《信 息披露事务管理制度》）的有关规定，结合公司实际情况，制定本制度。 第二条 自愿性信息披露是指虽未达到《证券法》《上市公司信息披露管理 办法》《股票上市规则》等相关法律法规规定的披露标准，但基于维护投资者利 益而由公司进行的自愿性的信息披露。公司应当根据相关法律法规、规范性文件、 《公司章程》《信息披露事务管理制度》以及本制度的规定，及时、准确、完整 地披露与投资者作出价值判断和投资决策 ...

睿智医药科技股份有限公司 关于董事辞职暨选举职工董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事辞职情况 睿智医药科技股份有限公司（以下简称"公司"）于近日收到公司非独立董 事樊世新先生的书面辞职报告。因公司内部工作调整，樊世新先生申请辞去公司 第六届董事会非独立董事、董事会审计委员会委员及董事会战略与可持续发展委 员会委员职务。该辞职报告自送达公司董事会之日起正式生效，樊世新先生辞职 后将继续在公司担任其他职务。樊世新先生的辞职不会导致公司董事会成员低于 法定最低人数。 二、选举职工董事的情况 证券代码：300149 证券简称：睿智医药 公告编号：2025-51 特此公告。 睿智医药科技股份有限公司 董事会 2025 年 7 月 8 日 附件： 樊世新先生简历 樊世新：男，1965 年出生，中国国籍，无永久境外居留权，大专学历。曾在 山西职工医学院工作，任教师；2014 年至 2016 年在浙江清华长三角研究院萧山 生物工程中心，任科技顾问，负责项目转化工作；2016 年至 2021 年在澳大利亚 纽卡斯尔大学健康与医学学院，任中国代表， ...

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with circuit board, CRO, and consumer electronics manufacturing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. Pharmaceutical Sector - The pharmaceutical sector experienced a strong opening, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Notable stocks included Lianhuan Pharmaceutical, which achieved a two-day limit up, and several others like Weixin Kang and Ha Sanlian hitting the daily limit [7][8]. - Fujilai (301258) surged to a limit up of 20% to reach a price of 39.28 CNY per share shortly after the market opened [8][9]. PCB Sector - PCB (Printed Circuit Board) stocks continued to strengthen, with companies like International Composite Materials and Yidong Electronics hitting the daily limit. Jin'an Guoji achieved a four-day limit up, while Honghe Technology recorded four limit ups in six days [12][13]. - The demand for high-end PCBs is rapidly increasing due to AI computing needs, leading to a significant supply-demand gap in AI PCBs this year. ASIC chip growth is expected to be the main driver of incremental demand for high-end PCBs by 2026 [14][15]. Company-Specific News - Ruisi Kanda faced a trading halt with a limit down of 9.95% due to allegations of information disclosure violations, leading to criminal measures against its executives [17][20]. - ST Huaming also experienced a limit down of 20.03% following administrative penalties for false disclosures in its financial reports [20].

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

Group 1 - The CRO concept sector experienced a decline of 0.53%, ranking among the top declines in concept sectors, with leading decliners including Lianhua Technology, Shengnuo Biology, and Meinuo Pharma [1][2] - Among the 24 stocks that rose, Sichuan Shuangma, Hanyu Pharmaceutical, and Meihao Medical had the highest increases of 3.14%, 1.98%, and 1.75% respectively [1][4] - The CRO concept sector saw a net outflow of 863 million yuan from major funds, with 47 stocks experiencing net outflows, and five stocks seeing outflows exceeding 30 million yuan [2][3] Group 2 - Lianhua Technology had the largest net outflow of major funds at 436 million yuan, followed by Ruizhi Pharmaceutical, WuXi AppTec, and Meinuo Pharma with outflows of 85 million yuan, 75 million yuan, and 48 million yuan respectively [2][3] - The stocks with the highest net inflows included Hanyu Pharmaceutical, Kailai Ying, and Sichuan Shuangma, with inflows of 37 million yuan, 17 million yuan, and 11 million yuan respectively [2][4] - The trading volume for Lianhua Technology was notably high at 21.98%, indicating significant trading activity despite the decline [3]

Summary of the Conference Call for Ruizhi Pharmaceutical Company Overview - **Company**: Ruizhi Pharmaceutical - **Industry**: Pharmaceutical and Biotechnology Key Points and Arguments Financial Performance - In Q1 2025, Ruizhi Pharmaceutical reported revenue of **261 million yuan**, a year-on-year increase of **11.37%** [2][4] - The net profit attributable to shareholders was **6.64 million yuan**, marking a return to profitability [2][4] - The company significantly reduced its non-deductible net profit loss to **1.57 million yuan**, a **94%** reduction in losses year-on-year [2][5] - For 2024, the company faced challenges with revenue dropping to **970 million yuan**, a **14.76%** decline, and a net loss of **226 million yuan**, although this was a **75.49%** improvement compared to the previous year [3] Strategic Initiatives - The company is implementing a comprehensive package strategy, providing one-stop solutions from IND to PCC, enhancing service capabilities across the entire chain [2][6] - Focus on high-value orders and investment in new modalities such as ADC, RDC, AOC, and PDC [2][6] - Initiated a partnership with leading companies in the ADC field to launch a new generation XDC conjugate drug R&D technology platform [2][7] Market Development - Emphasis on large clients in the domestic market, targeting traditional markets transitioning to innovation [2][8] - Optimizing the business development (BD) team for deeper engagement in the U.S. market and increasing exposure in emerging European markets [2][8] - Plans to establish new R&D centers on the U.S. East Coast and in the UK [2][8] Equity Incentive Plan - The company approved an equity incentive plan granting **52.61 million shares**, representing **10.57%** of total equity, to **124 core personnel** [2][9] - Performance targets include a **25%** increase in revenue and a return to profitability [2][9] Business Segment Insights - The small molecule drug segment is experiencing sluggish growth, needing significant effort to return to previous peak levels of **400-500 million yuan** [3][11] - The company is seeing rapid growth in high-risk related businesses, with domestic growth particularly boosted by recent large projects [3][11] ADC Business Capabilities - The company has comprehensive capabilities in the ADC sector, including chemistry, conjugation, and antibody development [2][12] - Currently rebuilding ABC CNC production capacity, with plans to initiate operations soon [2][12] Organizational Changes - The BD structure has been reformed to enhance domestic market engagement, which previously accounted for over **80%** of revenue from international orders [2][13] - New strategies include regional divisions and a focus on strategic client resources [2][13] Future Outlook - The management expresses confidence in achieving annual targets, supported by external market recovery and internal optimization [2][10] - The company is optimistic about future growth, especially in the innovative drug sector, as traditional pharmaceutical companies increase their investments [2][16][22] Investment Fund Strategy - Since 2022, the company has participated in investment funds to drive business development, leveraging government-guided funds for early-stage incubation [2][19] Market Recovery - The overseas market is showing signs of recovery, with a notable return of funds to primary markets [2][17] Emerging Market Trends - ADC, peptides, and small nucleotides are identified as high-growth areas, with the company securing multiple projects in these fields [2][18] Additional Important Insights - The company is focused on cost control while investing in platform development, including small nucleic acid drug platforms and ABC development [2][14] - The second quarter shows positive trends, with traditional pharmaceutical companies increasing their investment in innovative drugs [2][15]

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]